While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price in January. But this ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

First Horizon Advisors Inc. reduced its position in Merck & Co., Inc. by 8.7%, selling 15,566 shares in the 4th quarter, ...

Ligand originated, structured, and invested $50 million and led a syndicate of co-investors who invested $25 million in ...

Merck & Co. is facing a class action lawsuit over Gardasil sales projections. Learn how to recover losses with Levi & ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...